Biopharmaceutical companies isolate many types of proteins for use in experimental and therapeutic medicines. Unfortunately, when removed from their native environments, proteins become less stable. Unstable proteins are more prone to degradation from the primary stress mechanisms: mechanical and thermal (from manufacturing, storage and transport) and biological (from drug delivery). The challenge for biopharmaceutical companies...Read More
